Athira Pharma snags $85m Series B
Seattle-based Athira Pharma Inc, a developer of regenerative therapies focused on restoring brain function, has closed $85 million in Series B financing.
Seattle-based Athira Pharma Inc, a developer of regenerative therapies focused on restoring brain function, has closed $85 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination